Premium
A Pune-based drugmaker that counts two private equity firms as investors and recently started selling a medicine to treat COVID-19 patients with mild to moderate symptoms has raised fresh debt capital. Brinton Pharmaceuticals Ltd, which is backed by India Alternatives and Tata Capital Healthcare Fund, has secured debt capital from non-banking ......
This is a Premium article. Please subscribe or log in to read the full story!
Here's a selection of our recent premium content.
Already a member? Click here to log in.
